Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Living in a virus-controlled world

As the coronavirus pandemic continues to infect populations, though in some countries it is slowing, talk has shifted to re-opening economies, and to manufacturing a vaccine that drug companies hope will not only work, but can be distributed at large enough doses to provide ...
Richard (Rick) Mills | April 24, 2020 |

BioNTech, EXMceuticals, XPhyto - Covid-19 and legalizations offer potential

In recent months, the society around the globe has been going through a process of change of deceleration and standstill. Priorities have been redefined and implemented at record speeds in many places. Covid-19 serves as a catalyst for change for many people. The reasons can b...
Mario Hose | July 15, 2020 |

'Data Readouts Approaching in Two Pivotal Trials' for Biopharma Targeting Unmet Needs

The next steps for each of the programs are outlined in a Dawson James Securities report. In an Aug. 14 research note, Dawson James Securities analyst Jason Kolbert reported that Soligenix Inc. (SNGX:NASDAQ) "is now focused on the two pivotal programs, i...
Streetwise Reports | August 22, 2019 |

BioNTech, CureVac, Valeo Pharma - the license to print money

Those who solve problems or create desires can usually earn a lot of money. One of the most important requirements is that the solution is scalable and can be sold in large quantities. The solutions around the Corona pandemic are a particularly lucrative business, because ther...
Mario Hose | August 24, 2020 |

Buzz on the Bullboards: Volatility persists in the face of economic indicators

This week has proven to be a challenging one for investors on both sides of the border. Canada’s main stock index struggled to gain traction as Statistics Canada reported another rise in the Industrial Product Price Index for April, reflecting ongoing...
Jonathon Brown | May 30, 2024 |

The growing weaponization of space

In his recent State of the Union address, President Trump gave a shout-out to space exploration, highlighting the newly-created Space Force branch of the US Military, and NASA’s Artemis program of crewed lunar exploration. Artemis aims to put astronauts on ...
Richard (Rick) Mills | February 14, 2020 |

The Revolutionary Co. That’s Breaking Through the Blood Brain Barrier

(Click image to play video) Delivery of therapeutics across the blood-brain barrier (BBB) and into the brain has been the single greatest challenge to treating hundreds of common and rare neurological diseases, including brain cancers, neurodegenerative diseases...
Dave Jackson | December 1, 2020 |

Fineqia International brings investors lucrative, risk-mitigated opportunities

Fineqia International Inc. (CSE:FNQ) is a digital asset business. It makes investments from its own balance sheet, targeting early stage companies; businesses in blockchain, fintech, artificial intelligence and NFTs. Its platform also helps to brings crowd investors luc...
Brieanna McCutcheon | October 31, 2023 |

Developer of Oncology Therapeutics to Have 'Catalyst Rich' 2020

The near-term events expected to trigger movement of the biotech's share price are outlined in a ROTH Capital Partners report. In a Jan. 2 research note, ROTH Capital Partners analyst Jonathan Aschoff reported that he is assuming coverage on VBL Therapeutics (VBLT:NA...
Streetwise Reports | January 9, 2020 |

SWOT Analysis: Gold Production and Demand Fell In China In 2019

Strengths The best performing metal this week was gold, up 0.92 percent. Gold traders and analysts were split between bullish and neutral outlooks on gold ahead of next week’s Federal Reserve meeting, according to the weekly Bloomberg survey. Commodity...
Frank Holmes | January 27, 2020 |
1 2 3 4 5 6 7 8 9 10 ...